Unique Pharma, Pharmaceutical Import Profile — Congo Dr (DGFT 2022–2026)

Name: Unique Pharma, Pharmaceutical Import Records from India — 10 Products, $9.2M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Unique Pharma, — Pharmaceutical Importer Profile (2026) | 10 Products, $9.2M Trade | TransData Nexus

Unique Pharma,

Pharmaceutical Importer · Congo Dr · Antimalarial & Antiparasitic Focus · $9.2M Total Trade · DGFT Verified

Unique Pharma, is a pharmaceutical importer based in Congo Dr with a total trade value of $9.2M across 10 products in 7 therapeutic categories. Based on 304 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Unique Pharma, sources from 2 verified Indian suppliers, with Biomatrix Healthcare Private Limited accounting for 96.3% of imports.

Unique Pharma, — Import Portfolio & Supplier Network

Unique Pharma, import network — 10 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Unique Pharma,?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Biomatrix Healthcare Private Limited	$13.8M	863	96.3%
Zest Pharma	$530.7K	29	3.7%

Unique Pharma, sources from 2 verified Indian suppliers across 500 distinct formulations.

What Formulations Does Unique Pharma, Import?

Formulation	Value	Ships
Pain relief tablets (secours)	$427.9K	14
Artemether and lumefantrine	$328.3K	14
Pain relief tablets (secours) (as per	$252.2K	9
Paracetamol, phenylephrine	$240.2K	16
Cefotaxime 1000MG & sulbactum 500MG	$216.9K	7
Gauze cloth (1mt x 1mt)	$209.6K	11
Clindamycin hydrochloride capsules USP	$194.0K	6
Amoxicillin and potassium clavulanate	$181.9K	4
Benzalkonium chloride & chlorhexidine	$181.7K	6
Artemether and lumefantrine tablets	$178.9K	5
Sterilised water for injection	$170.6K	8
Gauze cloth (1 mtr x 1 mtr)	$157.5K	6
Ibuprofen tablets BP 400 MG (ipro 400)	$157.2K	5
Artemether and lumefantrine dispersibletablets (80 MG +480 MG) (luther dp dispersible) (as per inv)	$157.1K	4
Cefotaxime for injection USP 1000 MG and sterilised water for injection BP (ouicef)	$150.0K	3

Unique Pharma, imports 500 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 10 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Artesunate	Antimalarial & Antiparasitic	$4.3M	177	1.6%	5
2	Clindamycin	Antibiotics	$1.3M	26	1.4%	15
3	Amoxicillin	Antibiotics	$1.1M	21	0.2%	14
4	Phenylephrine	Respiratory & OTC	$950.0K	19	1.1%	12
5	Potassium	Nutritional Supplements	$850.0K	17	0.1%	18
6	Captopril	Cardiovascular	$232.1K	5	1.9%	5
7	Ornidazole	Advanced Antibiotics	$192.9K	17	1.1%	11
8	Protein	Nutritional Supplements	$153.0K	13	1.0%	12
9	Cephalexin	Antibiotics	$150.0K	3	0.0%	9
10	Ibuprofen Paracetamol	Combination Drugs	$112.5K	6	5.8%	2

Unique Pharma, imports 10 pharmaceutical products across 7 categories into Congo Dr totaling $9.2M.

Unique Pharma, — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Unique Pharma is a prominent pharmaceutical importer and distributor based in the Democratic Republic of Congo (DRC). Established with the mission to provide accessible and high-quality healthcare solutions across Africa, the company has expanded its presence to major African countries, earning the trust of regulators, healthcare professionals, and institutions.

Headquartered in Kinshasa, DRC, Unique Pharma operates with a robust distribution network, supplying a diverse range of pharmaceutical products, including branded formulations and generic medicines. The company's product portfolio spans various therapeutic areas such as gynecology, pediatrics, anti-infectives, anti-malarials, cardio-diabetics, and surgical products.

Unique Pharma's commitment to quality is evident in its stringent testing protocols and zero tolerance for process deviations. This dedication has led to the development of leading pharmaceutical brands like Sudrox, Hifer, and Triokit, which are widely accepted in the African market.

2Distribution Network

Unique Pharma's distribution network is strategically positioned to serve the vast expanse of the DRC. The company maintains warehouses in key cities, including Kinshasa, Lubumbashi, and Goma, ensuring efficient coverage of the country's diverse regions.

The logistics capabilities of Unique Pharma are designed to handle the complexities of the DRC's infrastructure, facilitating timely delivery of pharmaceutical products to hospitals, pharmacies, and healthcare centers. While the company's primary focus is on the DRC, its established network and reputation have enabled it to extend its reach to other African countries, contributing to the broader healthcare landscape.

3Industry Role

In the pharmaceutical supply chain of the DRC, Unique Pharma functions as a primary wholesaler and distributor. The company imports a wide array of finished pharmaceutical formulations from international suppliers, particularly from India, and supplies these products to local hospitals, pharmacies, and healthcare institutions.

Unique Pharma's role is pivotal in bridging the gap between international pharmaceutical manufacturers and the Congolese healthcare system, ensuring the availability of essential medicines across the country. The company's extensive distribution network and commitment to quality have solidified its position as a key player in the DRC's pharmaceutical sector.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Unique Pharma,

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Unique Pharma's sourcing strategy exhibits a high degree of concentration, with a significant majority of its pharmaceutical imports originating from India. Between 2022 and 2026, the company imported finished pharmaceutical formulations totaling $9.2 million USD across 304 shipments, with 90.9% of this value attributed to the top five products.

The primary supplier, BIOMATRIX HEALTHCARE PRIVATE LIMITED, accounted for 96.3% of the total import value, indicating a strong reliance on this single source. This concentration suggests a strategic choice to maintain consistent product quality and supply chain efficiency. However, such dependency also poses potential risks, including supply disruptions due to geopolitical issues, regulatory changes, or operational challenges faced by the supplier.

The stability of the relationship with BIOMATRIX HEALTHCARE PRIVATE LIMITED appears robust, given the volume and frequency of shipments. Nonetheless, Unique Pharma may consider diversifying its supplier base to mitigate risks associated with over-reliance on a single source.

2Supply Chain Resilience

Unique Pharma's supply chain resilience is closely tied to its sourcing strategy from India, particularly its dependence on BIOMATRIX HEALTHCARE PRIVATE LIMITED. While the company imports a diverse range of 500 unique pharmaceutical formulations, the heavy reliance on a single supplier for the majority of its imports could pose challenges in the event of supply chain disruptions.

Importing Pharmaceuticals into Congo Dr — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Congo Dr

1Regulatory Authority & Framework

The Congolese Pharmaceutical Regulatory Authority (ACOREP) is responsible for overseeing the importation, registration, and distribution of pharmaceutical products in the DRC. ACOREP ensures that all imported medicines meet the country's health and safety standards, safeguarding public health.

Key legislation governing pharmaceutical imports includes the Pharmaceutical Law, which outlines the requirements for drug registration, import licensing, and quality control. The law mandates that all imported medicines undergo a pre-shipment inspection and be registered with ACOREP before they can be marketed in the DRC.

The marketing authorization pathway for Indian generics involves obtaining a Certificate of Pharmaceutical Product (CPP) from the exporting country's regulatory authority, followed by registration with ACOREP. This process ensures that imported generics are of acceptable quality and efficacy, aligning with the DRC's health standards.

2Import Licensing & GMP

Import licensing in the DRC requires importers to secure an import license from an authorized commercial bank. Additionally, shipments valued over a specified amount must undergo a pre-shipment inspection by Bureau Veritas to verify compliance with Congolese regulations.

While Good Manufacturing Practice (GMP) certification is officially required for imported medicines, enforcement is often inconsistent. A Certificate of Pharmaceutical Product (CPP) is a critical document in the import process, serving as evidence of the product's quality and compliance with international standards.

Unique Pharma, — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Unique Pharma's product strategy focuses on therapeutic areas with high demand in the DRC, including anti-malarial and anti-infective treatments, as well as cardio-diabetic and surgical products. The company's import data indicates a significant emphasis on anti-malarial and anti-infective medications, reflecting the prevalence of these health concerns in the region.

The market demand for these products is driven by the high incidence of infectious diseases such as malaria and the growing burden of non-communicable diseases like diabetes and cardiovascular conditions. Unique Pharma's strategic focus on these areas aligns with the healthcare needs of the Congolese population, positioning the company as a key supplier of essential medicines.

2Sourcing Profile

Unique Pharma's sourcing strategy is predominantly centered on importing finished pharmaceutical formulations from India, particularly from suppliers like BIOMATRIX HEALTHCARE PRIVATE LIMITED.

TransData Nexus Research · DGFT trade data analysisMar 2026

Frequently Asked Questions — Unique Pharma,

What products does Unique Pharma, import from India?

Unique Pharma, imports 10 pharmaceutical products across 7 categories. Top imports: Artesunate ($4.3M), Clindamycin ($1.3M), Amoxicillin ($1.1M), Phenylephrine ($950.0K), Potassium ($850.0K).

Who supplies pharmaceuticals to Unique Pharma, from India?

Unique Pharma, sources from 2 verified Indian suppliers. The primary supplier is Biomatrix Healthcare Private Limited (96.3% of imports, $13.8M).

What is Unique Pharma,'s total pharmaceutical import value?

Unique Pharma,'s total pharmaceutical import value from India is $9.2M, based on 304 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Unique Pharma, focus on?

Unique Pharma, imports across 7 categories. The largest: Antimalarial & Antiparasitic (46.0%), Antibiotics (27.0%), Nutritional Supplements (10.8%).

Get Full Unique Pharma, Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Profile aggregates 2 company name variants from customs records. For current shipment-level data, contact TransData Nexus.